Article

ISTA Pharmaceuticals begins Vitrase shipments

Irvine, CA—ISTA Pharmaceuticals has begun shipping units of pure ovine hyaluronidase for injection (Vitrase) in two sizes.

Irvine, CA-ISTA Pharmaceuticals has begun shipping units of pure ovine hyaluronidase for injection (Vitrase) in two sizes.

The product, which increases the absorption and dispersion of anesthetics and other injected drugs, is available in its ovine form in the single-use, 200 USP units/ml and the lyophilized, ovine version in multipurpose, 6,200 USP units.

The FDA approved the larger unit in May, and the smaller unit in December. The May approval ended the drug's tenure on the FDA's drug shortage list, where it had been since the previous manufacturer withdrew it from the market in 2001.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.